Litcius/Paper detail

Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Dalong Zhu, Xiaoying Li, Jianhua Ma, Jiao’e Zeng, Shenglian Gan, Xiaolin Dong, Jing Yang, Xiaohong Lin, Hanqing Cai, Weihong Song, Xuefeng Li, Keqin Zhang, Qiu Zhang, Yibing Lu, Ruifang Bu, Huige Shao, Guixia Wang, Guoyue Yuan, Xingwu Ran, Lin Liao, Wenjuan Zhao, Ping Li, Li Sun, Lixin Shi, Zhaoshun Jiang, Yaoming Xue, Hongwei� Jiang, Quanmin Li, Zongbao Li, Maoxiong Fu, Zerong Liang, Lian Guo, Ming Liu, Chun Xu, Wenhui Li, Xuefeng Yu, Guijun Qin, Yang Zhou, Benli Su, Longyi Zeng, Houfa Geng, Yongquan Shi, Yu Zhao, Yi Zhang, Wenying Yang, Li Chen

2022Nature Medicine94 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboTolerabilityType 2 diabetesGlycated hemoglobinGlycemicInternal medicineAdverse effectClinical endpointHypoglycemiaRandomized controlled trialDiabetes mellitusGastroenterologyPharmacologyEndocrinologyInsulinPathologyAlternative medicinePancreatic function and diabetesMetabolism, Diabetes, and CancerDiabetes Management and Research
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial | Litcius